Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Consolidated Net Income (2021 - 2025)

Historic Consolidated Net Income for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to -$34.4 million.

  • Amylyx Pharmaceuticals' Consolidated Net Income rose 5270.41% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$148.9 million, marking a year-over-year increase of 4266.05%. This contributed to the annual value of -$301.4 million for FY2024, which is 71444.33% down from last year.
  • Amylyx Pharmaceuticals' Consolidated Net Income amounted to -$34.4 million in Q3 2025, which was up 5270.41% from -$41.4 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Consolidated Net Income ranged from a high of $22.1 million in Q2 2023 and a low of -$118.8 million during Q1 2024
  • Over the past 5 years, Amylyx Pharmaceuticals' median Consolidated Net Income value was -$35.9 million (recorded in 2025), while the average stood at -$34.3 million.
  • In the last 5 years, Amylyx Pharmaceuticals' Consolidated Net Income skyrocketed by 14080.75% in 2023 and then crashed by 765200.25% in 2024.
  • Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Consolidated Net Income stood at -$28.3 million in 2021, then tumbled by 54.54% to -$43.8 million in 2022, then soared by 110.29% to $4.5 million in 2023, then crashed by 924.69% to -$37.2 million in 2024, then rose by 7.49% to -$34.4 million in 2025.
  • Its Consolidated Net Income stands at -$34.4 million for Q3 2025, versus -$41.4 million for Q2 2025 and -$35.9 million for Q1 2025.